ArticleAmerican journal of preventive cardiology2025
Trends in utilization and cost of triglyceride-lowering therapies among Medicare beneficiaries: An analysis from the Medicare part D database.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 14 million U.S. adults may benefit from treatment of hypertriglyceridemia to reduce risk of atherosclerotic cardiovascular disease (ASCVD). While the evidence base for treatment of hypertriglyceridemia has significantly changed over time, patterns of utilization and spending on triglyceride-lowering therapies in the U.S. are not well-understood. Methods: We used the Medicare Part D Prescriber dataset from 2013 to 2021 to identify all generic and brand name formulations of triglyceride-lowering therapies (fibrates, omega-3 acid ethyl esters, and niacin). We assessed annual expenditures and number of beneficiaries, evaluated trends and assessed potential savings to Medicare if generic medications were used in place of brand names. Results: We identified seventeen oral triglyceride-lowering medications used from 2013-2021. There was a 22 % decline in beneficiaries receiving any triglyceride-lowering therapy and a 32 % reduction in Medicare spending over the study period. For fibrates, overall use declined by 21 % (from 1.6 million to 1.3 million beneficiaries) and spending declined by 67 % (from $735 million to $243 million). For omega-3 acid ethyl esters, overall use increased by 47 % (from 389k to 571k beneficiaries) and spending increased by 101 % (from $461 million to $925 million). For niacin, overall use declined by 87.3 % (from 445k to 56k beneficiaries) and spending declined by 92.9 % (from $431 million to $31 million). When generics became available, expenditure on and number of beneficiaries receiving brand name medications decreased. During the study period, $5.0 billion (41 %) was spent on brand name triglyceride-lowering therapies, and $1.5 billion could have been saved by switching to their respective generic versions when available. Conclusions: Among Medicare Part D beneficiaries, use and spending on fibrates and niacin declined, while use and spending on omega-3 acid ethyl esters increased. These trends likely reflect changes in the evidence base and guideline recommendations for hypertriglyceridemia treatment. While most beneficiaries received generic medications when available, substantial spending on brand name medications persists, indicating potential missed opportunities for cost savings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.